Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

被引:67
|
作者
Ahluwalia, Manmeet S. [1 ]
Reardon, David A. [2 ]
Abad, Ajay P. [3 ]
Curry, William T. [4 ]
Wong, Eric T. [5 ]
Figel, Sheila A. [6 ,7 ]
Mechtler, Laszlo L. [3 ]
Peereboom, David M. [1 ]
Hutson, Alan D. [8 ]
Withers, Henry G. [8 ]
Liu, Song [8 ]
Belal, Ahmed N. [9 ]
Qiu, Jingxin [10 ]
Mogensen, Kathleen M. [3 ]
Dharma, Sanam S. [6 ]
Dhawan, Andrew [11 ]
Birkemeier, Meaghan T. [6 ]
Casucci, Danielle M. [6 ,7 ]
Ciesielski, Michael J. [6 ,7 ]
Fenstermaker, Robert A. [6 ,7 ]
机构
[1] Cleveland Clin, Rose Ella Burkhardt Brain Tumor Ctr, Cleveland, OH USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[3] Roswell Pk Comprehens Canc Ctr, Dept Neurooncol, Buffalo, NY USA
[4] Harvard Med Sch, Massachusetts Gen Hosp Canc Ctr, Boston, MA USA
[5] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA USA
[6] Roswell Pk Comprehens Canc Ctr, Dept Neurosurg, Buffalo, NY USA
[7] MimiVax LLC, Buffalo, NY USA
[8] Roswell Pk Comprehens Canc Ctr, Biostat & Bioinformat, Buffalo, NY USA
[9] Roswell Pk Comprehens Canc Ctr, Dept Radiol, Buffalo, NY USA
[10] Roswell Pk Comprehens Canc Ctr, Dept Pathol, Buffalo, NY USA
[11] Cleveland Clin, Neurol Inst, Cleveland Hts, OH USA
关键词
PEPTIDE VACCINE; SURVIVIN; CANCER; EXPRESSION; GENE; RADIOTHERAPY; EXOSOMES; PATIENT; TUMORS; GRADE;
D O I
10.1200/JCO.22.00996
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE Despite intensive treatment with surgery, radiation therapy, temozolomide (TMZ) chemotherapy, and tumor-treating fields, mortality of newly diagnosed glioblastoma (nGBM) remains very high. SurVaxM is a peptide vaccine conjugate that has been shown to activate the immune system against its target molecule survivin, which is highly expressed by glioblastoma cells. We conducted a phase IIa, open-label, multicenter trial evaluating the safety, immunologic effects, and survival of patients with nGBM receiving SurVaxM plus adjuvant TMZ following surgery and chemoradiation (ClinicalTrials.gov identifier: NCT02455557).METHODS Sixty-four patients with resected nGBM were enrolled including 38 men and 26 women, in the age range of 20-82 years. Following craniotomy and fractionated radiation therapy with concurrent TMZ, patients received four doses of SurVaxM (500 mu g once every 2 weeks) in Montanide ISA-51 plus sargramostim (granulocyte macrophage colony-stimulating factor) subcutaneously. Patients subsequently received adjuvant TMZ and maintenance SurVaxM concurrently until progression. Progression-free survival (PFS) and overall survival (OS) were reported. Immunologic responses to SurVaxM were assessed.RESULTS SurVaxM plus TMZ was well tolerated with no serious adverse events attributable to SurVaxM. Of the 63 patients who were evaluable for outcome, 60 (95.2%) remained progression-free 6 months after diagnosis (prespecified primary end point). Median PFS was 11.4 months and median OS was 25.9 months measured from first dose of SurVaxM. SurVaxM produced survivin-specific CD8+ T cells and antibody/immunoglobulin G titers. Apparent clinical benefit of SurVaxM was observed in both methylated and unmethylated patients.CONCLUSION SurVaxM appeared to be safe and well tolerated. The combination represents a promising therapy for nGBM. For patients with nGBM treated in this manner, PFS may be an acceptable surrogate for OS. A large randomized clinical trial of SurVaxM for nGBM is in progress.
引用
收藏
页码:1453 / +
页数:16
相关论文
共 50 条
  • [11] Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?
    Zhao, Binghao
    Ma, Wenbin
    NEURO-ONCOLOGY, 2021, 23 (09) : 1614 - 1615
  • [12] Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme
    Gloria B. Roldán Urgoiti
    Amitabh D. Singh
    Jacob C. Easaw
    Journal of Neuro-Oncology, 2012, 108 : 173 - 177
  • [13] Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
    Stupp, Roger
    Hegi, Monika E.
    Neyns, Bart
    Goldbrunner, Roland
    Schlegel, Uwe
    Clement, Paul M. J.
    Grabenbauer, Gerhard G.
    Ochsenbein, Adrian F.
    Simon, Matthias
    Dietrich, Pierre-Yves
    Pietsch, Torsten
    Hicking, Christine
    Tonn, Joerg-Christian
    Diserens, Annie-Claire
    Pica, Alessia
    Hermisson, Mirjam
    Krueger, Stefan
    Picard, Martin
    Weller, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : 2712 - 2718
  • [14] Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma
    Maraka, Stefania
    Groves, Morris D.
    Mammoser, Aaron G.
    Melguizo-Gavilanes, Isaac
    Conrad, Charles A.
    Tremont-Lukats, Ivo W.
    Loghin, Monica E.
    Obrien, Barbara J.
    Puduvalli, Vinay K.
    Sulman, Erik P.
    Hess, Kenneth R.
    Aldape, Kenneth D.
    Gilbert, Mark R.
    de Groot, John F.
    Yung, W. K. Alfred
    Penas-Prado, Marta
    CANCER, 2019, 125 (03) : 424 - 433
  • [15] Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide
    Stupp, R
    Dietrich, PY
    Kraljevic, SO
    Pica, A
    Maillard, I
    Maeder, P
    Meuli, R
    Janzer, R
    Pizzolato, G
    Miralbell, R
    Porchet, F
    Regli, L
    de Tribolet, N
    Mirimanoff, RO
    Leyvraz, S
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) : 1375 - 1382
  • [16] Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
    Vieito, Maria
    Simonelli, Matteo
    de Vos, Filip
    Moreno, Victor
    Geurts, Marjolein
    Lorenzi, Elena
    Macchini, Marina
    van den Bent, Martin J.
    Del Conte, Gianluca
    de Jonge, Maja
    Martin-Soberon, Maria Cruz
    Amoroso, Barbara
    Sanchez-Perez, Tania
    Zuraek, Marlene
    Hanna, Bishoy
    Aronchik, Ida
    Filvaroff, Ellen
    Chang, Henry
    Mendez, Cristina
    Arias Parro, Marina
    Wei, Xin
    Nikolova, Zariana
    Sepulveda, Juan Manuel
    NEURO-ONCOLOGY ADVANCES, 2022, 4 (01)
  • [17] Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma
    Wen, PY
    Gigas, DC
    MacDonald, L
    Batchelor, TT
    Schiff, D
    Xu, R
    Ramakrishna, N
    Weaver, S
    Kracher, J
    Bradshaw, J
    Levy, B
    Bailey, E
    Kesari, S
    Maher, EA
    Henson, J
    Black, PM
    NEURO-ONCOLOGY, 2004, 6 (04) : 385 - 385
  • [18] PHASE I STUDY OF VANDETANIB WITH RADIOTHERAPY AND TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA
    Drappatz, Jan
    Norden, Andrew D.
    Wong, Eric T.
    Doherty, Lisa M.
    LaFrankie, Debra C.
    Ciampa, Abigail
    Kesari, Santosh
    Sceppa, Christine
    Gerard, Mary
    Phan, Phuong
    Schiff, David
    Batchelor, Tracy T.
    Ligon, Keith L.
    Young, Geoffrey
    Muzikansky, Alona
    Weiss, Stephanie E.
    Wen, Patrick Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (01): : 85 - 90
  • [19] Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma
    Schiff, David
    Huse, Jason
    Wen, Patrick
    NEURO-ONCOLOGY, 2014, 16 (06) : 769 - 769
  • [20] A PHASE I STUDY OF SORAFENIB WITH RADIATION AND TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA
    Colman, Howard
    Gilbert, Mark
    Yung, W. K. Alfred
    Aldape, Ken
    De Groot, John
    Conrad, Charles
    Levin, Victor
    Groves, Morris
    Loghin, Monica
    Chris, Pelloski
    Puduvalli, Vinay
    NEURO-ONCOLOGY, 2011, 13 : 61 - 61